Lineage- and Stage-Specific Oncogenicity of IRF4
- 28 July 2022
- journal article
- review article
- Published by Elsevier in Experimental Hematology
- Vol. 114, 9-17
Abstract
No abstract availableKeywords
This publication has 107 references indexed in Scilit:
- An incoherent regulatory network architecture that orchestrates B cell diversification in response to antigen signalingMolecular Systems Biology, 2011
- Initial genome sequencing and analysis of multiple myelomaNature, 2011
- Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsiesLaboratory Investigation, 2010
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphomaNature, 2009
- Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphomaHuman Pathology, 2009
- Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control TH2 responsesNature, 2009
- IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotypeProceedings of the National Academy of Sciences, 2008
- Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomasLeukemia, 2008
- IRF4 addiction in multiple myelomaNature, 2008
- Notch–RBP-J signaling is involved in cell fate determination of marginal zone B cellsNature Immunology, 2002